Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5823MR)

This product GTTS-WQ5823MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5823MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8251MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ2098MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ2164MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ11371MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ4014MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ4543MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ15192MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ10622MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW